Previous Article | Next Article ![]()
Journal of Virology, June 2000, p. 5357-5362, Vol. 74, No. 11
Laboratory of Molecular Virology and
Epidemiology, AIDS Research Center, National Institute of Infectious
Diseases, Shinjuku, Tokyo 162-8640,1 and
Naha Prefectural Hospital, Naha, Okinawa
902,2 Japan
Received 23 December 1999/Accepted 28 February 2000
Changes in the drug susceptibility, gene lineage, and deduced amino
acid sequences of the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) subtype E following
3'-azido-3'-deoxythymidine (AZT) monotherapy or
AZT-2',3'-dideoxyinosine combination therapy were examined with
sequential virus isolates from a single family. The changes were
compared to those reported for HIV-1 subtype B, revealing striking
similarities in selected phenotype and amino acids independent of
differences in the RT backbone sequences that constantly distinguish
the two subtypes. Particularly, identical amino acid substitutions were
present simultaneously at four different positions (D67N, K70R, T215F,
and K219Q) for high-level AZT resistance. These data suggest that HIV-1
subtypes E and B evolve convergently at the phenotypic and amino acid
levels when the nucleoside analogue RT inhibitors act as selective forces.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Convergent Evolution of Reverse Transcriptase (RT)
Genes of Human Immunodeficiency Virus Type 1 Subtypes E and B following
Nucleoside Analogue RT Inhibitor Therapies
*
Corresponding author. Mailing address: Laboratory of
Molecular Virology and Epidemiology, AIDS Research Center, National
Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo
162-8640, Japan. Phone: (81)-3-52851111. Fax: (81)-3-52851129. E-mail:
hirosato{at}nih.go.jp.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»